EUPRAXIA PHARMACEUTICALS INC (EPRX.CA) Fundamental Analysis & Valuation

TSX:EPRX • CA29842P1053

Current stock price

9.83 CAD
-0.2 (-1.99%)
Last:

This EPRX.CA fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

1

1. EPRX.CA Profitability Analysis

1.1 Basic Checks

  • In the past year EPRX has reported negative net income.
  • EPRX had a negative operating cash flow in the past year.
  • In the past 5 years EPRX always reported negative net income.
  • In the past 5 years EPRX always reported negative operating cash flow.
EPRX.CA Yearly Net Income VS EBIT VS OCF VS FCFEPRX.CA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 2025 -10M -20M -30M

1.2 Ratios

  • The Return On Assets of EPRX (-44.78%) is better than 65.22% of its industry peers.
  • The Return On Equity of EPRX (-47.02%) is better than 69.57% of its industry peers.
Industry RankSector Rank
ROA -44.78%
ROE -47.02%
ROIC N/A
ROA(3y)-85.67%
ROA(5y)-84.11%
ROE(3y)-465.58%
ROE(5y)-338.07%
ROIC(3y)N/A
ROIC(5y)N/A
EPRX.CA Yearly ROA, ROE, ROICEPRX.CA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 1K -1K -2K

1.3 Margins

  • EPRX does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
EPRX.CA Yearly Profit, Operating, Gross MarginsEPRX.CA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 2024 2025

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

8

2. EPRX.CA Health Analysis

2.1 Basic Checks

  • Compared to 1 year ago, EPRX has more shares outstanding
  • Compared to 5 years ago, EPRX has more shares outstanding
  • There is no outstanding debt for EPRX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
EPRX.CA Yearly Shares OutstandingEPRX.CA Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 2024 2025 10M 20M 30M 40M 50M
EPRX.CA Yearly Total Debt VS Total AssetsEPRX.CA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M 80M

2.2 Solvency

  • An Altman-Z score of 60.12 indicates that EPRX is not in any danger for bankruptcy at the moment.
  • EPRX has a Altman-Z score of 60.12. This is amongst the best in the industry. EPRX outperforms 100.00% of its industry peers.
  • There is no outstanding debt for EPRX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 60.12
ROIC/WACCN/A
WACCN/A
EPRX.CA Yearly LT Debt VS Equity VS FCFEPRX.CA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20M -20M 40M 60M 80M

2.3 Liquidity

  • A Current Ratio of 15.12 indicates that EPRX has no problem at all paying its short term obligations.
  • EPRX has a Current ratio of 15.12. This is amongst the best in the industry. EPRX outperforms 100.00% of its industry peers.
  • A Quick Ratio of 15.12 indicates that EPRX has no problem at all paying its short term obligations.
  • EPRX's Quick ratio of 15.12 is amongst the best of the industry. EPRX outperforms 100.00% of its industry peers.
Industry RankSector Rank
Current Ratio 15.12
Quick Ratio 15.12
EPRX.CA Yearly Current Assets VS Current LiabilitesEPRX.CA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M 80M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

1

3. EPRX.CA Growth Analysis

3.1 Past

  • EPRX shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -18.82%.
EPS 1Y (TTM)-18.82%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-32.23%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • Based on estimates for the next years, EPRX will show a quite strong growth in Earnings Per Share. The EPS will grow by 19.76% on average per year.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y39.04%
EPS Next 2Y16.25%
EPS Next 3Y6.83%
EPS Next 5Y19.76%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPRX.CA Yearly Revenue VS EstimatesEPRX.CA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2029 2030 2031 2032 2033 100M 200M 300M 400M 500M
EPRX.CA Yearly EPS VS EstimatesEPRX.CA Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 0 1 -1 2 3

More info and screens

Find the best growth stocksShow best growing peers

0

4. EPRX.CA Valuation Analysis

4.1 Price/Earnings Ratio

  • EPRX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for EPRX. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
EPRX.CA Price Earnings VS Forward Price EarningsEPRX.CA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
EPRX.CA Per share dataEPRX.CA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y16.25%
EPS Next 3Y6.83%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. EPRX.CA Dividend Analysis

5.1 Amount

  • EPRX does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

EPRX.CA Fundamentals: All Metrics, Ratios and Statistics

EUPRAXIA PHARMACEUTICALS INC

TSX:EPRX (4/16/2026, 7:00:00 PM)

9.83

-0.2 (-1.99%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-12
Earnings (Next)05-07
Inst Owners30.93%
Inst Owner ChangeN/A
Ins Owners16.03%
Ins Owner ChangeN/A
Market Cap593.93M
Revenue(TTM)N/A
Net Income(TTM)-38.58M
Analysts85.45
Price Target16.18 (64.6%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-65.55%
Min EPS beat(2)-112.68%
Max EPS beat(2)-18.41%
EPS beat(4)0
Avg EPS beat(4)-49.13%
Min EPS beat(4)-112.68%
Max EPS beat(4)-18.41%
EPS beat(8)3
Avg EPS beat(8)-30.41%
EPS beat(12)6
Avg EPS beat(12)-19.65%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)8.13%
PT rev (3m)30.95%
EPS NQ rev (1m)19.68%
EPS NQ rev (3m)-4.76%
EPS NY rev (1m)9.35%
EPS NY rev (3m)2.16%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 5.27
P/tB 5.27
EV/EBITDA N/A
EPS(TTM)-1.68
EYN/A
EPS(NY)-1.02
Fwd EYN/A
FCF(TTM)-0.66
FCFYN/A
OCF(TTM)-0.65
OCFYN/A
SpS0
BVpS1.86
TBVpS1.86
PEG (NY)N/A
PEG (5Y)N/A
Graham Number0 (-100%)
Profitability
Industry RankSector Rank
ROA -44.78%
ROE -47.02%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-85.67%
ROA(5y)-84.11%
ROE(3y)-465.58%
ROE(5y)-338.07%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 247.79%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 15.12
Quick Ratio 15.12
Altman-Z 60.12
F-Score6
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)134.74%
Cap/Depr(5y)191.66%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-18.82%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-32.23%
EPS Next Y39.04%
EPS Next 2Y16.25%
EPS Next 3Y6.83%
EPS Next 5Y19.76%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-44.83%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year24.17%
EBIT Next 3Y10%
EBIT Next 5Y29.94%
FCF growth 1Y3.18%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y4.81%
OCF growth 3YN/A
OCF growth 5YN/A

EUPRAXIA PHARMACEUTICALS INC / EPRX.CA Fundamental Analysis FAQ

Can you provide the ChartMill fundamental rating for EUPRAXIA PHARMACEUTICALS INC?

ChartMill assigns a fundamental rating of 3 / 10 to EPRX.CA.


What is the valuation status for EPRX stock?

ChartMill assigns a valuation rating of 0 / 10 to EUPRAXIA PHARMACEUTICALS INC (EPRX.CA). This can be considered as Overvalued.


What is the profitability of EPRX stock?

EUPRAXIA PHARMACEUTICALS INC (EPRX.CA) has a profitability rating of 1 / 10.